Philanthropic Pour: Quilceda Creek’s Exclusive Club Fuels Cancer Research

WOODINVILLE, WA – November 17, 2025 – Quilceda Creek, a highly-regarded Washington State Cabernet Sauvignon producer, has donated $335,000 to the Cancer Research Institute (CRI) through the sale of limited-release library wines to its exclusive membership list. The funds will directly support CRI’s groundbreaking research into cancer immunotherapy, a promising field focused on harnessing the body’s own immune system to fight cancer.

A Legacy of Excellence & Giving

Founded in 1978, Quilceda Creek has built a reputation for producing world-class Cabernet Sauvignons with limited production, making access to its wines highly coveted. The winery operates on a unique membership model, where a select group of enthusiasts receive priority access to its vintages. This dedicated community proved instrumental in the recent fundraising effort. The success of the campaign, exceeding its initial $250,000 goal, underscores the winery's commitment to both quality wine production and philanthropic initiatives.

“The response from our members was truly remarkable,” said a winery representative. “They understand the importance of supporting vital research, and they were eager to contribute to a cause that impacts so many lives.” This isn't Quilceda Creek’s first foray into charitable giving. The winery previously donated $365,000 each to the Restaurant Employee Relief Fund in 2020, during the height of the pandemic, and to World Central Kitchen in 2022, supporting humanitarian efforts in Ukraine.

The Power of Immunotherapy and CRI’s Role

The Cancer Research Institute is a leading non-profit organization dedicated to advancing cancer immunotherapy. Unlike traditional treatments like chemotherapy and radiation, which attack cancer cells directly, immunotherapy aims to empower the patient’s immune system to recognize and destroy cancer. This approach holds immense promise, offering the potential for longer-lasting remissions and improved quality of life for patients.

“Immunotherapy is revolutionizing cancer treatment,” explained a CRI spokesperson. “We’ve seen incredible progress in recent years, with immunotherapy now approved for many different types of cancer. But there’s still much work to be done, and donations like this are crucial to accelerating our research.” The CRI's high ratings from charity watchdogs like Charity Navigator (a 4-star rating with a 100% score) and GuideStar reflect its financial transparency and commitment to maximizing its impact. CRI directs a significant percentage of its funding – historically between 83% and 90% – directly to research programs and grants.

Leveraging Exclusivity for a Worthy Cause

The recent fundraising campaign centered around the release of library wines – vintages held back for maturation – to Quilceda Creek’s private membership. This strategy not only generated significant funds for CRI but also offered members a unique opportunity to acquire highly sought-after wines. The library wines released – vintages 2015 and later – command a premium on the secondary market, providing a substantial value for members while simultaneously supporting cancer research.

“The appeal of these wines is multi-faceted,” said a wine enthusiast and member of the Quilceda Creek allocation list. “They’re exceptionally well-made, and the opportunity to support a worthy cause makes the purchase even more meaningful.” The winery’s pricing for these wines to members was significantly lower than market value, providing added incentive for participation. This approach demonstrates a savvy understanding of its customer base and a commitment to aligning its business practices with its philanthropic goals. Quilceda Creek's wines consistently receive high ratings from esteemed publications like Robert Parker Wine Advocate and Wine Spectator, often achieving perfect 100-point scores, further enhancing their desirability among collectors and connoisseurs.

The impact of this donation will be felt across CRI’s wide range of research programs, including laboratory research, translational studies, and clinical trials. CRI funds scientists around the globe, supporting groundbreaking discoveries and developing innovative immunotherapies. Their iAtlas platform, an open-access bioinformatics resource, provides researchers with invaluable data and tools to accelerate their work. The funds will also contribute to CRI’s efforts to train the next generation of cancer immunologists and to increase diversity within the field.